Analogs of the RSK inhibitor SL0101: Optimization of in vitro biological stability

Abstract

The Ser/Thr protein kinase, RSK, is important in the etiology of tumor progression including invasion and motility. The natural product kaempferol-3-O-(3″,4″-di-O-acetyl-α-Lrhamnopyranoside), called SL0101, is a highly specific RSK inhibitor. Acylation of the rhamnose moiety is necessary for high affinity binding and selectivity. However, the acetyl groups can be cleaved by esterases, which accounts for the poor in vitro biological stability of SL0101. To address this problem a series of analogues containing acetyl group replacements were synthesized and their in vitro stability evaluated. Monosubstituted carbamate analogues of SL0101 showed improved in vitro biological stability while maintaining specificity for RSK. These results should facilitate the development of RSK inibitors derived from SL0101 as anticancer agents. Keywords SL0101; RSK inhibitor; RSK-specific; Breast cancer; Protein kinaseThe members of the p90 ribosomal S6 kinase (RSK) family of Ser/Thr protein kinases have been shown to play a role in a number of different cancers as key drivers of proliferation and metastasis. [1][2][3][4][5][6][7][8] These discoveries have been enabled in part by our report of the identification and isolation of the RSK inhibitor SL0101 (1, Figure 1). 9 SL0101 is a flavonoid glycoside (kaempferol 3-O-(3″,4″-di-O-acetyl-α-L-rhamnopyranoside)) isolated from Forsteronia refracta, a variety of dogbane found in the South American rainforest. SL0101 is highly specific for RSK, inhibiting RSK1/2 but not unrelated kinases nor the closely related kinases MSK1 and p70S6K1. 2,9,10 SL0101 inhibits the proliferation of breast and prostate cancer lines but not their normal counterparts even though it inhibits RSK activity in all the lines. 1,5,9 Thus it appears that some cancer cells have become addicted to RSK, which suggests that RSK may be a potential new target for cancer therapeutics. SL0101, owing to its exquisite specificity, is a compelling lead compound from which to begin the process of identifying drug-like RSK inhibitors. © 2012 Elsevier Ltd. All rights reserved. * Corresponding author. Tel: 434-924-1152; fax: 434-924-1236; mh6cu@virginia.edu. Supplementary Material: Experimental procedures and compound characterization for all new compounds can be found online at Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will under go copy editing, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. We and others have reported the total synthesis and biological evaluation of SL0101 and a number of analogues, with the ultimate goal of developing an anticancer drug that targets RSK. [11][12][13][14][15] These analogues have provided key information about t...

Myricetin inhibits proliferation and induces apoptosis and cell cycle arrest in gastric cancer cells

“…Compared with normal cell lines, RSK2 protein level is significantly higher in cancer cells [23][24][25][26][27][28]. The NTD of RSK2 transduces its substrates to accept the RSK2 activation signal [29].…”

RSK Promotes Prostate Cancer Progression in Bone through ING3, CKAP2, and PTK6-Mediated Cell Survival

“…In addition, BI-D1870 also has effects on polo-kinase 1 activity (31), leading to failure of cells to undergo cytokinesis in BI-D1870-treated C4-2B4 cells (data not shown). Development of RSK inhibitors with improved affinity, biological stability, and membrane permeability of SL0101 have been reported (33, 34). Thus, it is likely that a clinically applicable inhibitor for RSK will be available in the near future.…”

Synthesis and Evaluation of Novel RSK Inhibitors in a Living Human Breast Model

“…In the previous year of the project (Year 1) the in vitro biological stability of SL0101 analogues was improved by modifying the substitution on sugar portion of SL0101 to replace the biologically labile acetates at the 3' and 4' positions of the carbohydrate ring with relatively biologically inert carbamates (5). Importantly, the carbamate analogues retained specificity for RSK as measured by their selective inhibition of the growth of cancer over normal cell lines.…”